First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia
Pembrolizumab-axitinib improved efficacy for East Asian patients with untreated clear cell mRCC, consistent with results from the global population. Safety was manageable. ClinicalTrials.gov identifier: NCT02853331.
Authors
- Yoshihiko Tomita (ORCID: https://orcid.org/0000-0002-7465-9591)
- L. Rhoda Molife
- Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
- Ryuichi Mizuno (ORCID: https://orcid.org/0000-0002-1507-1421)
- Brian I. Rini (ORCID: https://orcid.org/0000-0002-2212-080X)
- Satoshi Anai (ORCID: https://orcid.org/0000-0002-3552-1311)
- Go Kimura (ORCID: https://orcid.org/0000-0003-0088-9324)
- Woo Kyun Bae (ORCID: https://orcid.org/0000-0003-0267-1943)
- John Wen‐Cheng Chang (ORCID: https://orcid.org/0000-0001-8373-5691)
- Hirotsugu Uemura (ORCID: https://orcid.org/0000-0002-3665-9523)
- Rodolfo F. Perini (ORCID: https://orcid.org/0009-0002-4400-5260)
- Chihiro Kondoh (ORCID: https://orcid.org/0000-0001-6189-4851)
- Satoshi Tamada (ORCID: https://orcid.org/0000-0002-7102-3408)
- Thomas B. Powles (ORCID: https://orcid.org/0000-0001-7760-4724)
- Hyo Jin Lee (ORCID: https://orcid.org/0000-0001-8378-3001)
- Chao-Hsiang Chang
- Jianxin Lin
- Hsiao-Jen Chung (ORCID: https://orcid.org/0000-0003-4865-1251)
Institutions
- Chonnam National University (KR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Cleveland Clinic (US)
- Chang Gung University of Science and Technology (TW)
- National Yang Ming Chiao Tung University (TW)
- Osaka Prefecture University (JP)
- Queen Mary University of London (GB)
- Chang Gung University (TW)
- China Medical University (TW)
- Chungnam National University (KR)
- Barts Health NHS Trust (GB)
- The Royal Free Hospital (GB)
- Taipei Veterans General Hospital (TW)
- MSD (UK) Limited (United Kingdom) (GB)
- Chonnam National University Hospital (KR)
- Kindai University Hospital (JP)
- Keio University Hospital (JP)
- Nara Medical University Hospital (JP)
- Niigata University Medical and Dental Hospital (JP)
- St Pancras Hospital (GB)
- China Medical University Hospital (TW)
- National Cancer Center Hospital East (JP)
- Chonnam National University Hwasun Hospital (KR)
- Nippon Medical School Hospital (JP)
- Toranomon Hospital (JP)
- University College London (GB)
- Nara Medical University (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1093/jjco/hyae182
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Exelixis
- Arrowhead Pharmaceuticals
- Mirati Therapeutics
- Incyte
- Seagen
- Eisai
- Astellas Pharma
- Ipsen
- Chugai Pharmaceutical
- MSD K.K.